About this policy
The comment period for the MolDX: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis DL39424 Local Coverage Determination (LCD) began on 09/01/2022 and ended on 10/15/2022. The notice period for L39424 begins on 08/31/2023 and will become effective on 10/15/2023. The comments below were received from the provider community.
Codes in this policy
Code numbers and each code’s status as the policy records it. CPT code descriptions are left out of this page, as are the passages that cite CPT codes; the official document has them.
Backwork has no codes on record for this policy. Check the source.